68051-B-PCT-US/JPW

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known

Attorney Docket Number

Substitute for form 1449/PTO **Application Number** 10/591,195 Filing Date September 29, 2006 INFORMATION DISCLOSURE First Named Inventor Liat Hayardeny STATEMENT BY APPLICANT Art Unit 1649 (Use as many sheets as necessary) **Examiner Name** Kolker, Daniel E.

Sheet

			U. S. PATEN	DOCUMENTS	
Examiner Imitals*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (F known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	<sup>US-</sup> 5,800,808	09-01-1998	Konfino, et al.	
	2	<sup>US-</sup> 5,981,589	11-09-1999	Konfino, et al.	
	3	<sup>US-</sup> 6,048,898	04-11-2000	Konfino, et al.	
	4	<sup>US-</sup> 6,054,430	04-25-2000	Konfino, et al.	
	5	<sup>US-</sup> 6,214,791	04-10-2001	Amon, et al.	
	6	<sup>US-</sup> 6,342,476	01-29-2002	Konfino, et al.	
	7	<sup>US-</sup> 6,362,161	03-26-2002	Konfino, et al.	
	8	<sup>US-</sup> 6,514,938	02-04-2003	Gad, et al.	
	9	<sup>US-</sup> 6,620,847	09-16-2003	Konfino, et al.	
	10	<sup>US-</sup> 6,800,285	10-05-2004	Rodriguez	
	11	<sup>US-</sup> 6,800,287	10-05-2004	Gad, et al.	
	12	<sup>US-</sup> 6,939,539	09-06-2005	Konfino, et al.	
	13	<sup>US-</sup> 7,022,663	04-042006	Gilbert, et al.	
	14	<sup>US-</sup> 7,033,582	04-25-2006	Yong, et al.	
	15	us- 7,074,580	07-22-2006	Gad, et al.	
	16	<sup>US-</sup> 7,163,802 B2	01-16-2007	Gad, et al.	
	17	<sup>US-</sup> 7,199,098	04-03-2007	Konfino, et al.	
	18	<sup>US-</sup> 7,279,172	10-09-2007	Aharoni, et al.	
	19	<sup>US-</sup> 2003-0170729 A1	09-11-2003	Klinger	

			IGN PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	T
	1,40.	Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	T⁵
	29	WO 98/30227	07-16-1998	Yeda Research and Developme	ent CO., LTD.	
	30	WO 00/05250	02-03-2000	Yeda Research and Developme	ent CO., LTD.	Т
	31	WO 00/18794	04-06-2000	<del></del>	+	广
	32	WO 00/27417	05-18-2000	Yeda Research and Developme		H
	33	WO 01/60392	08-23-2001	Yeda Research and Developm	ent CO., LTD.	1
	34	WO 01/93828	12-13-2001	Teva Pharmaceuticals Industri	es. LTD.	

Examiner	Date	
Signature		
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

68051-B-PCT-US/JPW

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/591,195 **Filing Date** September 29, 2006 INFORMATION DISCLOSURE First Named Inventor Liat Hayardeny STATEMENT BY APPLICANT Art Unit 1649 (Use as many sheets as necessary) Examiner Name Kolker, Daniel E.

Attorney Docket Number

			U. S. PATENT	T DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (# Amount)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relovant Passages or Relevan Figures Appear
	20	<sup>US-</sup> 2005-0170004	08-04-2005	Rosenberger	-
	21	<sup>US-</sup> 2006-0122113	06-08-2006	Pinchasi, et al.	
	22	<sup>US-</sup> 2006-0172942 A1	08-03-2006	Dolitzky	
	23	<sup>US-</sup> 2006-0052586	03-09-2006	Dolitzky	
	24	<sup>US-</sup> 2007-0021341 A1	01-25-2007	Sela, et al.	
	25	<sup>US-</sup> 2007-0021324 A1	01-25-2007	Dolitzky, et al.	
	26	<sup>US-</sup> 2007-0048794 A1	03-01-2007	Gad, et al.	
	27	<sup>US-</sup> 2007-0054857	03-08-2007	Pinchasi, et al.	
	28	<sup>US-</sup> 11/590,338	10-30-2006	Pinchasi, et al.	
		US-			
		UŞ-			

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
····	110.	Country Code 1 Number 4 Kind Code (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	T
	35	WO 01/97846	12-27-2001	Teva Pharmaceuticals Industri	es, LTD.	
	36	WO 03/048735	06-12-2003	Teva Pharmaceuticals Industri	es, LTD.	Г
7.5	59	WO 04/43995	05-27-2004	APOTEX PHARMACHEM	I INC.	Γ
2000	60	WO 06/50122	05-11-2006	Sandoz AG		
	61	WO 08/06026		MOMENTA PHARMACE	EUTICALS, INC.	Г

Examiner		Date	
Signature	l l		1
Signature	,	Considered	1
			l

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \*Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer PROFESS CIBCOMERGINE PACKETS 118 Advanced by A 2324 AASO.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Uniter the Panenwork Reduction Act of 1995, no persons are required to reso

Substitute for form 1449/PTO		Complete if Known
	Application Number	10/591,195
INFORMATION DISCLOSURE	Filing Date	September 29, 2006
STATEMENT BY APPLICANT	First Named Inventor	Liat Hayardeny
(Use as many sheets as necessary)	Art Unit	1649
(USB as many shoets as necessary)	Examiner Name	Kolker, Daniel E.
Sheet 3 of 5	Attorney Docket Number	68051-B-PCT-US/JPW

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	37	Bornstein et al., "Treatment of MS with a Synthetic Polypeptide: Preliminary Results" Ann. Neurol., 1980, 8, 117	
	38	Bornstein et al., "Treatment of MS with synthetic polypeptide: preliminary results" Trans. Am. Neurol. Assoc., 1980, 105, 348-350	
	39	Bornstein et al., "MS: Trial of a synthetic polypeptide" Ann. Neurol., 1982, 11, 317-319	
	40	Bornstein et al., "Clinical trials of Copolymer 1 in MS" Ann. N.Y. Acad. Sci. (USA), 1984, 366-372	
	41	Bornstein et al., "Clinical Trials of a synthetic polypeptide (Copolymer 1) for the treatment of MS" Immunol. & Clin. Aspects of MS, 1984, 144-150	
	42	Bornstein et al., "MS: Clinical Trials of a Synthetic Polypeptide, Copolymer 1" Neurol., 1985, 35 (Suppl. 1), 103	
	43	Bornstein, "Cop 1 may be beneficial for patients with exacerbating remitting form of MS" Adv. Ther., 1987, 4, 206	
	44	Bornstein, et al., "A Pilot trial of Cop 1 in Exacerbating remitting MS" New Eng. J. Med., 1987, 317 (7), 408-414	
	45	Bornstein, et al., "Clinical Experience with COP-1 in MS" Neurol., 1988, 38 (Suppl. 2.), 66-69	
	46	Bornstein, et al., "Rationale for Immunomodulating Therapies of MS" Neurol., 1988, 38 (Suppl. 2.), 80-81R	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>&</sup>quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 02/29/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information, unless it contains a wild OMB control under Huder the Paparent Poduction Act of 1995, no namena are required

Substitut	te for form 1449/PTO		<u></u>	Complete if Known			
				Application Number	10/591,195		
INF	ORMATION	I DIS	CLOSURE	Filing Date	September 29, 2006		
STATEMENT BY APPLICANT				First Named Inventor	Liat Hayardeny		
	(Use as many she	nate se n	acaeeanul	Art Unit	1649	-	
	(OSC as many site	ous as n	ocossary,	Examiner Name	Kolker, Daniel E.		
Sheet	4	of	5	Attorney Docket Number	68051-B-PCT-US/JPW		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	47	Bornstein et al., "Pilot Trial of COP-1 in Chronic Progressive MS: Preliminary report" Intl. MS Conf.1988, in Elsevier Sci. Publi. 1989, 225-232	
	48	Bornstein et al., "Clinical Trials of Cop 1 in MS" Handbook of MS, 1990, 469-480	
	49	Bornstein et al., "A Placebo-controlled, Double-Blind, Randomized Two-center, Pilot Trial of Cop 1 in Chronic Progressive MS" Neurol., 1991, 41, 533-539	
	50	Bornstein et al., "Treatment of MS with Copolymer 1" Treatmt. of MS, Trial Design., 1992, 173-198US5,800,808	
	51	Bornstein, "Clinical Experience: Hopeful Prospects in MS," Hosp Prac. (Off. Ed.) May 15, 1992 vol. 27 (No. 5) L135-138, 141-142, 145-158	
	52	Kalkers et al., "The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study" in Multiple Sclerosis, 2002, vol. 8, issue 6, pages 532-533	
	53	Sela et al., "Glatiramer acetate in the treatment of multiple sclerosis" in Expert Opin. Pharmacother., 2001, vol.2, no.7, pages 1149-1165	
	54	Copaxone® (glatiramer acetate injection), prescribing information, http://www.copaxone.com/pdf/PrescribingInformation.pdf	
	55	International Preliminary Report on Patentability issued by the International Bureau of WIPO dated December 24, 2007 in connection with International Application No. PCT/US2005/0007072	
	56	PCT International Search Report issued November 30, 2007 for International Application Publication No. PCT/US2005/0007072	

	Examiner	Date
i	Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Approved for use through 02/29/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
OF COMMERCE OF INFORMATION UNIQUE AND ADMINISTRATION OF INFORMATION OF IN Hayler the Personnel Padustion Act of 1005, as assessed as

Substitut	e for form 1449/PTO			Complete if Known		
				Application Number	10/591,195	
INFO	DRMATION	N DIS	CLOSURE	Filing Date	September 29, 2006	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Liat Hayardeny	
	(Use as many sh			Art Unit	1649	
(Use as many sheets as necessary)				Examiner Name	Kolker, Daniel E.	
Sheet	5	of	5	Attorney Docket Number	68051-B-PCT-US/JPW	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	57	Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/AU) on November 30, 2007 in connection with International Application No. PCT/US2005/0007072		
	58	"COPAXONE®" in Physician's Desk Reference, Medical Economics Co., Inc., Montvale, NJ, 2002, 3115		

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.